MX2009011384A - Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular. - Google Patents

Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.

Info

Publication number
MX2009011384A
MX2009011384A MX2009011384A MX2009011384A MX2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A MX 2009011384 A MX2009011384 A MX 2009011384A
Authority
MX
Mexico
Prior art keywords
agonist
cellular immunity
adjuvant combinations
nkt activator
optional antigen
Prior art date
Application number
MX2009011384A
Other languages
English (en)
Inventor
Cory Ahonen
Randolph Noelle
Original Assignee
Immurx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immurx Inc filed Critical Immurx Inc
Publication of MX2009011384A publication Critical patent/MX2009011384A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/38—Antigens from snakes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Se divulgan combinaciones adyuvantes que comprenden por lo menos un activador de NKT, tal como alfa-galactosilceramida (a-Gal-Cer) o iGb3, un agonista de CD40 y opcionalmente un antígeno. También se proporciona el uso de estos adyuvantes inmunes para el tratamiento de varias enfermedades crónicas tales como cánceres.
MX2009011384A 2007-04-25 2008-04-25 Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular. MX2009011384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90797607P 2007-04-25 2007-04-25
PCT/US2008/005341 WO2008133983A1 (en) 2007-04-25 2008-04-25 Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity

Publications (1)

Publication Number Publication Date
MX2009011384A true MX2009011384A (es) 2010-03-18

Family

ID=39925993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011384A MX2009011384A (es) 2007-04-25 2008-04-25 Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.

Country Status (10)

Country Link
US (3) US8802098B2 (es)
EP (1) EP2150277B1 (es)
JP (1) JP5331100B2 (es)
KR (1) KR20100025514A (es)
CN (1) CN101730546B (es)
AU (1) AU2008246149B2 (es)
CA (1) CA2685125A1 (es)
HK (1) HK1140959A1 (es)
MX (1) MX2009011384A (es)
WO (1) WO2008133983A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
CA2950109C (en) 2000-10-27 2019-02-19 John W. Hadden Vaccine immunotherapy for immune suppressed patients
EP2150277B1 (en) 2007-04-25 2013-02-27 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity
ES2679043T3 (es) * 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
ES2667476T3 (es) 2009-12-08 2018-05-11 Irx Therapeutics, Inc. Método para invertir la supresión inmunitaria de células de Langerhans
JP6456306B2 (ja) * 2013-02-20 2019-01-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ｉＮＫＴ細胞の活性化
JP6121597B1 (ja) * 2016-06-09 2017-04-26 株式会社スリービー 免疫応答活性化サイトカイン産生促進剤およびＴｈ１７細胞分化促進剤
CN113209302B (zh) * 2020-01-20 2022-11-18 成都医学院 一种具有抗肿瘤作用的药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US20040258688A1 (en) * 1995-01-31 2004-12-23 Daniel Hawiger Enhanced antigen delivery and modulation of the immune response therefrom
US20020136722A1 (en) * 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
RU2375077C2 (ru) * 2002-05-02 2009-12-10 Юниверсити Оф Коннектикут Хелт Сентер Использование белков теплового шока для повышения эффективности терапий антителами
EP2572715A1 (en) * 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
JP4939926B2 (ja) * 2003-02-14 2012-05-30 アノシス・インコーポレーテッド 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド
AU2004268616B2 (en) * 2003-08-25 2010-10-07 3M Innovative Properties Company Delivery of immune response modifier compounds
NZ548325A (en) * 2003-12-25 2009-07-31 Kirin Pharma Kk Mutants of anti-CD40 antibody
CA2577009C (en) 2004-08-27 2017-05-02 Steven A. Porcelli Ceramide derivatives as modulators of immunity and autoimmunity
WO2006029010A2 (en) 2004-09-03 2006-03-16 The University Of Chicago Methods of activating nkt cells
EP2251418B1 (en) * 2004-10-07 2021-03-17 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006071848A2 (en) * 2004-12-28 2006-07-06 The Rockefeller University Glycolipids and analogues thereof as antigens for nk t cells
US7868159B2 (en) * 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
KR100764678B1 (ko) 2005-07-13 2007-10-09 재단법인서울대학교산학협력재단 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물
US7421888B2 (en) * 2005-12-12 2008-09-09 Southwest Research Institute Regenerative system for testing torque converters and other transmission coupling devices
US20070269406A1 (en) 2005-12-14 2007-11-22 Ichim Thomas E Transcatheter tumor immunoembolization
EP2150277B1 (en) * 2007-04-25 2013-02-27 Immurx, Inc. Adjuvant combinations of nkt activator, cd40 agonist, and optional antigen, the use through inducing synergistic cellular immunity

Also Published As

Publication number Publication date
AU2008246149B2 (en) 2013-09-12
KR20100025514A (ko) 2010-03-09
US20150004163A1 (en) 2015-01-01
JP2010525065A (ja) 2010-07-22
AU2008246149A1 (en) 2008-11-06
EP2150277A4 (en) 2011-02-16
HK1140959A1 (en) 2010-10-29
US9238067B2 (en) 2016-01-19
EP2150277B1 (en) 2013-02-27
US20100247537A1 (en) 2010-09-30
CN101730546A (zh) 2010-06-09
CN101730546B (zh) 2013-04-24
EP2150277A1 (en) 2010-02-10
JP5331100B2 (ja) 2013-10-30
US20160158348A1 (en) 2016-06-09
CA2685125A1 (en) 2008-11-06
US10463731B2 (en) 2019-11-05
US8802098B2 (en) 2014-08-12
WO2008133983A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
MX2009011384A (es) Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.
PH12019500518A1 (en) Oligosaccharide mixture and food product comprising this mixture, especially infant formula
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
CR20150242A (es) Terapia adyuvante con inhibidores de quinasa de la familia tec
IN2012DN02736A (es)
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
MX2011010977A (es) Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
MX2009008926A (es) Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
MX2011007930A (es) Conjugados de insulina cristalina.
MX2009003325A (es) Vacuna que comprende un adyuvante de emulsion de aceite en agua.
MX343870B (es) Compuestos que contienen mesógeno.
GB0515353D0 (en) Food
EP1718315A4 (en) HIGH-DOSE USE AND SHORT INTERVAL OF SULFATE POLYSACCHARIDES IN THE TREATMENT OF INFECTIONS
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
CL2014000775A1 (es) Compuestos derivados de estra-1,3,5(10),16-tetraen-3-carboxamida; inhibidores de akr1c3; medicamentos que los contienen; y su uso para el tratamiento y/o la prevencion de endometriosis, dismenorrea, acne, alopecia, madurez sexual precoz, cancer de mama, cancer de pulmon, epoc, obesidad y dolor inflamatorio, entre otras.
CL2007002382A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento del cancer a la piel.
EP2094293A4 (en) TISSUE ANTIGEN ACTIVATION OF THE IMMUNE RESPONSE FOR THE TREATMENT OF CANCER
IN2014CN03454A (es)
WO2007150008A3 (en) Polypeptides from african swine virus as vaccines for preventive and therapeutic use
MX2010003415A (es) Proceso ex vivo, rápido y eficiente para la obtención de células presentadoras de antígenos activadas, útiles para las terapias contra el cáncer y enfermedades relacionadas con el sistema inmunológico.
CY1116914T1 (el) ΧΡΗΣΗ ΒΕΝΖΥΔΑΜΙΝΗΣ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΕΙΩΝ ΕΞΑΡΤΩΜΕΝΩΝ ΑΠΟ ΤΗΝ p40
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
EP2035018A4 (en) PATHOGENIC DEHYDRATION THROUGH ADMINISTRATION OF EQUILIBIOTIC COMPOUND
LV14606A (lv) Jauns XII faktora inhibitors
WO2009008888A8 (en) African swine virus polypeptides as vaccines and its therapeutic use thereof

Legal Events

Date Code Title Description
FG Grant or registration